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bjectives This study evaluated safety and efﬁcacy of upfront thrombus aspiration during primary per-
utaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction
STEMI).
ackground Distal embolization during primary PCI results in reduced myocardial perfusion and
oor clinical outcomes.
ethods The VAMPIRE (VAcuuM asPIration thrombus REmoval) study was a prospective, random-
zed, controlled multicenter trial conducted in 23 institutions. Patients (N  355) presenting within
4 h of STEMI symptoms onset were randomized to primary PCI with (n  180) or without (n 
75) upfront thrombus aspiration using Nipro’s TransVascular Aspiration Catheter (Osaka, Japan).
esults The TransVascular Aspiration Catheter reached the lesion in 100% of cases. It successfully
rossed the target obstruction in 86% without any delay in procedure time or time to reperfusion;
hereas macroscopic thrombi were removed in 75% of the cases. Procedure success was similar be-
ween groups (98.9% vs. 98.3%). There was a trend toward lower incidence of slow or no reﬂow
primary end point—deﬁned as a Thrombolysis In Myocardial Infarction ﬂow grade 3) in patients
reated with aspiration versus conventional primary PCI (12.4% vs. 19.4%, p  0.07). Rate of myocardial
lush grade 3 was higher in the aspiration group (46.0% vs. 20.5%, p  0.001). Aspiration was most ef-
ective in patients presenting after 6 h of symptoms onset (slow ﬂow rate: 8.1% vs. 37.6%, p  0.01).
onclusions This study suggested the safety of primary PCI with upfront thrombectomy using a
ovel device in patients with STEMI. The study showed a trend toward improved myocardial perfu-
ion and lower clinical events in patients treated with aspiration. Patients presenting late after STEMI
ppear to beneﬁt the most from thrombectomy. (J Am Coll Cardiol Intv 2008;1:424–31) © 2008 by
he American College of Cardiology Foundation
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425eperfusion therapy in patients presenting with ST-
egment elevation myocardial infarction (STEMI) remains
uboptimal. Abnormal tissue-level myocardial perfusion has
een shown to increase infarct size and reduce survival, in
pite of successful epicardial coronary reperfusion (1–7).
hus, approaches to improve results of primary percutane-
us coronary intervention (PCI) have been proposed. Pri-
ary PCIs facilitated by various adjunctive pharmacological
herapies have been attempted, but the benefit of such
trategies is questionable (8–10). The hypothesis that distal
rotection or thrombectomy in addition to primary PCI
mprove myocardial salvage in patients with STEMI has
lso been attempted (11–13). Similarly, these studies failed
o demonstrate a clear benefit of thrombectomy (11–13).
he results of these previous investigations challenge our
urrent understanding of the importance of thrombus em-
olism as the cause of microvascular dysfunction and poor
utcomes after reperfusion therapy (14–19). Failure to
ffectively aspirate materials, inadequate timing of deploy-
ent of distal protection devices or use of these devices
ithout upfront aspiration, and typical learning curve for
andling new devices particularly in emergency situations
ay have contributed to the perceived failure of thrombec-
omy strategies in previous studies. The TransVascular
355 Patients Randomized
Primary End Points
178 Included in Analysis of
Angiographical Myocardial
Perfusion; Slow flow / no
reflow, TIMI flow grade, 
blush score, cTFC
Primary End Points
171 Included in Analysis of
Angiographical Myocardial
Perfusion; Slow flow / no
reflow, TIMI flow grade, 
blush score, cTFC
Secondary End Points
115 Included in Analysis of 
ST-Segment Resolution
170 Included in Analysis of 
8-m Major Adverse Cardiac 
Events
135 Included in Analysis of 
Follow-up Angiography and
LVG at 6 m
93 Included in Analysis of BNP
at 6 m
Secondary End Points
105  Included in Analysis of 
ST-Segment Resolution
158 Included in Analysis of 
8-m Major Adverse Cardiac 
Events
135 Included in Analysis of 
Follow-up Angiography and
LVG at 6 m
80 Included in Analysis of BNP
at 6 m
180 Patients  Assigned to 
Undergo PCI With
Thrombus Aspiration
175 Patients  Assigned to 
Undergo PCI Without
Thrombus Aspiration
Figure 1. Randomization Flow
The ﬁgure indicates the patient randomization and ﬂow of the VAMPIRE
(VAcuuM asPIration thrombus REmoval) study. BNP  brain natriuretic pep-
tide; cTFC  corrected Thrombolysis in Myocardial Infarction frame count;
LVG  left ventriculography; PCI  percutaneous coronary intervention;a
TIMI Thrombolysis In Myocardial Infarction.spiration Catheter (TVAC) (Nipro, Osaka, Japan) has a
nique distal tip in the shape of a duck bill and possesses a
ide aspiration lumen, which should improve aspiration
erformance (20). This device has been tested previously
nd showed good technical performance (20). Thus, the
resent study was planned to evaluate the safety and efficacy
f upfront thrombus aspiration strategy using the novel
VAC device in patients with STEMI.
ethods
tudy design and eligibility. The VAMPIRE (VAcuuM
sPIration thrombus REmoval) study was a prospective
andomized multicenter trial performed in compliance with
he provisions of the Declaration of Helsinki regarding
linical investigations in humans. The study was approved
y the institutional review boards of all the investigational
ites and written informed con-
ent was obtained from all pa-
ients. Patients were enrolled
rom July 1, 2003, to January 1,
005, and followed up to Janu-
ry 1, 2006. Patient randomiza-
ion and study flow are shown in
igure 1.
Individuals eligible for enroll-
ent were 21 years old or older
ith acute myocardial infarction
resenting more than 30 min
ut 24 h after symptom onset,
ith 2 mm or more of ST-
egment elevation in 2 or more
ontiguous leads or with a pre-
umably new left bundle-branch
lock. Major criteria for exclu-
ion were presence of primary
hrombolysis prior to random-
zation, cardiogenic shock, history of cardiac arrest, history
f coronary bypass surgery, chronic renal failure (Cr 2.0
g/dl) or hemodialysis, left main disease, or target vessel
2.5 mm or 5 mm in diameter. There were no further
xclusion criteria.
CI procedure. Patients were pretreated with aspirin and
ntravenous heparin boluses were administered during the
rocedure to maintain an activated clotting time 300 s.
he PCI was performed according to standard techniques
ith the use of 7-F guiding catheters. Aspiration was
erformed using TVAC, which is a single lumen rapid-
xchange aspiration shaft, compatible with 7-F guiding
atheters and has a dedicated vacuum pump (20). No
spiration was performed prior to or following PCI in the
ontrol group. The use of bare metal stents was at the
iscretion of the attending physicians and the goal was to
Abbreviations
and Acronyms
CK  creatine kinase
CK-MB  creatine kinase-
myocardial band
cTFC  corrected
Thrombolysis In Myocardial
Infarction frame count
ECG  electrocardiographic/
electrocardiogram
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
TVAC  TransVascular
Aspiration Catheterchieve Thrombolysis In Myocardial Infarction (TIMI)
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426ow grade 3 with 10% residual stenosis. No drug eluting
tents were allowed. Left ventriculography was performed
rior to PCI. The use of thrombolytic agents or glyco-
rotein IIb/IIIa inhibitors was not allowed. Procedure
uccess was defined as successful dilation of the target lesion
o residual stenosis 50% without major adverse cardiac
vents.
ost-PCI management. All patients received oral aspirin and
iclopidine. Cilostazol was allowed as an alternative agent to
eplace ticlopidine in cases of intolerance. Patients were
tarted on angiotensin-converting enzyme inhibitors within
4 h after the PCI and oral beta-blockers if not
ontraindicated.
tudy end points. The primary end point of this study was
he incidence of slow flow or no reflow during primary PCI
efined as a TIMI flow grade 3 not attributable to
issection, occlusive thrombus, or epicardial spasm that was
valuated by an independent core laboratory. Secondary end
oints were coronary flow and myocardial perfusion imme-
iately after PCI, as assessed by TIMI flow grade, corrected
IMI frame count (cTFC), and myocardial blush score.
ther secondary end points were time and magnitude of
T-segment resolution, peak creatine kinase (CK) and
reatine kinase-myocardial band (CK-MB) measured every
h for 24 h after the procedure, angiographic in-stent late
umen loss at 6 months, left ventricular function as deter-
ined by angiography at 6 months, brain natriuretic peptide
evels at 6 months, and major adverse clinical events as a
omposite of death, recurrence of myocardial infarction, and
arget lesion revascularization over 8 months.
All patients were scheduled for angiographic follow-up at
months and clinical visits at 1, 3, 6, and 8 months. Data
nalysis was performed by an independent clinical research
rganization (Cardiocore Japan, Tokyo, Japan). Clinical
vents were adjudicated by an independent committee.
ngiographic analysis. Coronary angiograms were analyzed
y an independent core laboratory (K. Kozuma, MD, at
ardiocore Japan). Analysts were blinded to clinical data.
ngiographic TIMI flow grade was estimated visually,
sing standardized procedures. The cTFC was measured
ith a frame counter on a digital film viewer analyzing the
umber of cine frames required for contrast to reach a
tandardized landmark. Results were corrected for 30
rames/s and the frame counts for the left anterior descend-
ng artery were divided by 1.7 because of the difference in
ength, as described previously (21). In the presence of an
ccluded vessel (visual TIMI flow grade 0 to 1), cTFC was
et to a value of 100. The occurrence of slow flow or no
eflow (TIMI flow grade decreasing from 2 or 3 to 0 or 1
uring the procedure) was assessed. Myocardial blush grade
as assessed immediately after the procedure and at the
-month follow-up. The TIMI flow, cTFC, and myocardial
lush grade were assessed as described previously
2,3,21,22), in each case by 2 experienced analysts following ipecific standard operating procedures of the core labora-
ory. Interobserver variability of the blush score was 91%
etween the 2 analysts involved in this study. In cases of
isagreement between assessments from different analysts,
eassessment was performed together until consensus was
btained. Quantitative coronary angiography and left ven-
riculography were performed by means of QCA-
ardiovascular Measurement System, version 5.1 (MEDIS,
eiden, the Netherlands). Distal embolization was defined
s the migration of a filling defect or the distal occlusion of
he target vessel or 1 of its branches at the end of procedure.
lectrocardiographic (ECG) analysis. A 12-lead ECG was
cquired at admission, immediately after PCI, 3 to 6 h after
CI, at discharge, and 6 months after PCI. The ECG was
nalyzed by an independent core laboratory (Cardiocore
apan). The ST-segment levels were measured 60 ms after
he J point in the most abnormal lead. The percentage
esolution of ST-segment elevation was categorized using
he Schroder classification as complete (70%), partial
30% to 70%), or absent (30%) (23,24).
tatistical methods. The test hypothesis was that the inci-
ence of the primary end point in the control group is
igher than in the study group. We estimated a 25%
ncidence of slow flow or no reflow in the control group,
aking into consideration the range of previously reported
ata in similar populations (23% to 37%) (1,25,26). We
xpected an 11% incidence of slow flow/no flow in the
spiration group, based on previous observations (27) and
n our own unpublished data. Thus, a total sample size of
71 patients in each arm would provide 90% power to detect
difference in the primary end point between groups (1 
1%; 2  25%) using 2 group chi-square tests with a 0.05
-sided significance level. Considering potential dropouts
uring the study, the sample size in each arm was set at 175
atients. All analyses were performed according to the
ntent-to-treat principle. Categorical variables were pre-
ented as frequency values and were compared using the
hi-square test. Continuous variables were expressed as
ean standard deviation and were compared by using the
tudent t test.
esults
rom July 1, 2003, to January 1, 2005, 362 patients were
nrolled. Seven patients were excluded from the study
fter the enrollment: 2 because of errors in the diagnosis
f STEMI, 2 withdrew the informed consent, and 3
atients were protocol violations due to inadequate cor-
nary artery diameters. A total of 355 patients with
TEMI within 24 h of symptoms onset were randomized
o receive either PCI with thrombus aspiration using
VAC (n  180) or PCI alone (n  175) at 23 hospitalsn Japan. Baseline clinical and angiographic characteris-
t
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427ics were well matched between the 2 randomized groups
Tables 1 and 2).
rocedural results. The TVAC reached the lesion in 100%
f the patients as a primary device, but operators were able
o cross the target obstruction with the TVAC without
re-dilation in 83% of cases. In 3% of cases, device crossing
as achieved after balloon dilation. The TIMI flow grade 2
r 3 immediately after aspiration was achieved in 90.7% of
atients randomized to aspiration as compared with 47.4%
fter pre-balloon wire manipulation in the control group.
here were no coronary perforations in either group. There
ere no differences in procedural success rate, time from
atheterization laboratory door to TIMI flow grades 2 or 3,
r procedural time (Table 2). The incidence of coronary
issection and final distal embolism rate was significantly
ower in the aspiration group. Macroscopic thrombus
nd/or plaque debris were removed in 75.6% of cases (42.5%
f red thrombus, 18.7% of white thrombus, 10.6% of red
nd white thrombus, and 3.1% of yellow plaques and white
hrombus).
yocardial reperfusion end points. Angiographic measures
f myocardial perfusion were generally better in patients
reated with thrombectomy and primary PCI compared
ith standard therapy (Table 3). The primary end point,
ate of slow flow or no reflow, was achieved in 12.5% of
atients in the aspiration group versus 19.4% in the control
roup (p  0.07) (Table 3, Fig. 2). Myocardial blush grade
as significantly better in the thrombus aspiration group
ompared with conventional primary PCI (p  0.001).
here was no significant difference in ST-segment resolu-
ion, peak CK or peak CK-MB release between the 2
roups (Table 3).
ther angiographic end points. Data is presented in Table 4.
uantitative analyses of the target vessel and left ventricular
Table 1. Baseline Clinical Characteristics
Characteristics
Thrombus
Aspiration
(n  180)
No Thrombus
Aspiration
(n  175)
p
Value
Age, yrs 63.2  10.6 63.5  9.9 0.81
Male gender, % 80.6 77.7 0.51
Body mass index, kg/m2 24.1 24.3 0.54
Hypertension, % 54.8 59.0 0.45
Hyperlipidemia, % 50.0 48.5 0.78
Diabetes, % 23.3 29.9 0.16
Insulin use, % 3.6 3.1
Smoking
Current smoking, % 56.6 50.9 0.26
Ex-smoker, % 12.1 9.3
Family history of CAD, % 13.9 14.4 0.89
Previous PCI, % 3.4 5.2 0.42
Killip class 1, % 11.2 8.4 0.17
Onset-to-hospital, h 4.5  5.0 5.2  5.5 0.13pCAD coronary artery disease; PCI percutaneous coronary intervention.unction at baseline or follow-up were similar between
roups (Table 4). Brain natriuretic peptide levels at 6
onths showed a lower number in the aspiration group
ompared with the control, though the difference did not
each statistical significance.
linical outcome. During hospitalization, 1 patient died in
ach group. Another patient had subacute thrombosis and
omplicated repeat myocardial infarction in the control
roup. The 8-month major adverse cardiac event rate was
ignificantly lower in the thrombus aspiration group (12.9%
s. 21.0%, p  0.05) mainly due to low target lesion
evascularization rates in patients with late reperfusion of
etween 6 and 24 h (Table 5).
ubgroup analysis of early and late reperfusion. Patients
ere stratified into an early (6 h from symptoms) and a
ate (6 h from symptoms) reperfusion. The strategy of
hrombectomy and primary PCI produced consistent im-
rovement in all angiographic and clinical outcome mea-
ures compared with conventional primary PCI in patients
Table 2. Baseline Angiographic Data and Procedural Results
Thrombus
Aspiration
(n  178)
No Thrombus
Aspiration
(n  171)
p
Value
Target vessels, % 0.54
LAD 50.3 52.0
LCX 11.4 11.0
RCA 38.3 37.0
Lesion type, % 0.94
A 9.4 11.3
B1 28.1 28.9
B2 47.5 45.3
C 15.0 14.5
Baseline TIMI ﬂow grade, % 0.49
0/1 74.6 75.3
2 18.6 15.3
3 6.8 9.4
Stent use, % 94.1 93.4 0.79
IABP and/or PCPS use, % 9.4 13.4 0.25
Transfemoral approach, % 94.8 92.4 0.34
GP IIb/IIIa inhibitors, % 0 0 1
Procedural success, % 98.9 98.3 0.64
Coronary dissection, % 2.3 8.8 0.01
Distal embolism, % 16 29 0.02
Vascular access complication, % 2.9 4.1 0.54
From ER door to TIMI 2 to 3, min 105.6  61.0 114.6  178.2 0.27
From cath lab to TIMI 2 to 3, min 54.0  30.0 56.4  62.4 0.31
Procedural time, min 87.0  32.4 93.6  78.6 0.16
Fluoroscopy time, min 26.5  14.3 23.1  14.5 0.03
ER  emergency room; GP  glycoprotein; IABP  intra-aortic balloon pumping; LAD  left
anterior descending; LCX left circumflex; PCPSpercutaneous cardiopulmonary support; RCA
 right coronary artery; TIMI Thrombolysis In Myocardial Infarction.resenting late after STEMI (Table 6).
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428iscussion
he strategy of primary PCI with upfront thrombus
spiration using the TVAC device may be safe and was
ssociated with improved clinical outcomes in the VAM-
IRE study. There was a trend toward better reperfusion
arameters, including the primary end point of slow or no
eflow phenomena during PCI, among patients who
nderwent aspiration. In particular, patients presenting
etween 6 and 24 h after symptoms onset appear to
enefit the most from the thrombectomy strategy used in
he present study. This subgroup of patients experienced
etter reperfusion parameters and lower incidence of
dverse clinical events when treated with aspiration as
ompared with conventional primary PCI. The rate of
low or no reflow was 6 percentage points lower in the
ontrol population than anticipated, which may explain
he reduced statistical power to detect statistical differ-
nces in the primary end point between groups. Recent
tudies reported after the initiation of our trial have
Table 3. Angiographic Assessment of Myocardial Perfusion, ST-Segment
Resolution, and CK
Thrombus
Aspiration
No Thrombus
Aspiration
p
Value
Myocardial perfusion n  178 n  171
Slow ﬂow/no reﬂow, % 12.4 19.4 0.07
Final myocardial blush grade, % 0.001
0/1 17.1 37.1
2 36.9 42.4
3 46.0 20.5
Final TIMI ﬂow grade, % 0.08
0 0.0 0.0
1 2.3 1.2
2 10.2 18.2
3 87.5 80.6
Final cTFC 26.0  17.2 27.9  16.2 0.15
ST-segment resolution, % (post-
procedural)
n  115 n  105
30 33.9 40.9 0.514
30–70 33.9 32.4
70 32.2 26.7
ST-segment resolution, %
(3 to 6 h later)
n  113 n  105
30 27.4 23.8 0.685
30–70 31.9 37.1
70 40.7 39.1
Maximum CK (U/l) n  160 n  160
3,141  2,438 3,391  2,653 0.189
Maximum CK-MB subunit (U/l) n  110 n  110
297  344 502  1,370 0.067
CK  creatine kinase; CK-MB  creatine kinase-myocardial band; cTFC  corrected TIMI flow
count; other abbreviation as in Table 2.hown similarly low rates of slow flow rates (11% to 13%)n patients treated with conventional primary PCI with-
ut thrombectomy or distal protection (1–3).
In the published randomized studies so far, the AiMI (A
rospective, Randomized, Controlled Trial of Thrombec-
omy with the AngioJet in Acute Myocardial Infarction)
rial tested the benefit of AngioJet as an adjunct to direct
CI in 480 patients with STEMI. The group randomly
ssigned to the AngioJet group had significantly larger
nfarct sizes, worse angiographic measures, and a higher
ncidence of adverse clinical events than patients assigned to
he usual care group. Furthermore, the extensive use of
acemakers might have contributed to poor outcomes in-
reasing the risks of cardiac tamponade in the AiMI trial. In
he VAMPIRE trial, the baseline infarct sizes and angio-
raphic measures were similar between the groups and
acemaker use was not extensive. In the DEAR-MI (De-
hrombosis to Enhance Acute Reperfusion in Myocardial
nfarction) trial (28), the use of catheter thrombectomy in a
andomized study of 148 patients with STEMI was asso-
iated with better myocardial reperfusion, lower CK release,
ower risk of distal embolization, and lower risk of no
eflow. The results of the DEAR-MI trial were consistent
ith the VAMPIRE study. In the X-AMINE ST (X-Sizer
0 5 10 15 20 25
TVAC
non-TVAC
slow flow / no reflow (%)
P=0.07
A
37.1
17.1 36.9
42.4
46.0
20.5
0% 20% 40% 60% 80% 100%
TVAC
non-TVAC
Blush 0&1 Blush 2 Blush 3
P<0.001
B
Figure 2. Coronary Flow Immediately After the Procedure
Figure shows the end point results for the TransVascular Aspiration Cathe-
ter (TVAC) group versus non-TVAC group. (A) The primary end point of this
study: complication rate of slow ﬂow or no reﬂow (p  0.07). (B) The sec-
ondary end point: myocardial blush grade (p  0.001).
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429n Acute Myocardial Infarction Patients for Negligible
mbolization and Optimal ST Resolution) trial (29), The
djunctive use of X-Sizer was evaluated before PCI in 201
Table 4. QCA and LVG
Thrombus
Aspiration
No Thrombus
Aspiration
p
Value
QCA n  177 n  170
MLD pre (mm) 0.21 0.37 0.17 0.36 0.18
Reference pre (mm) 2.70 0.69 2.68 0.73 0.40
% stenosis pre 92.6 12.7 93.7 12.9 0.21
MLD post (mm) 2.22 0.54 2.22 0.56 0.50
Reference post (mm) 2.92 0.61 2.90 0.62 0.38
% stenosis post 23.5 13.0 22.8 12.3 0.32
QCA at 6-month follow-up n  135 n  135
MLD (mm) 1.73 0.68 1.71 0.75 0.44
Reference (mm) 2.72 0.60 2.73 0.72 0.46
% stenosis 35.9 22.1 38.2 22.5 0.20
Late loss (mm) 0.49 0.74 0.52 0.66 0.37
Binary restenosis rate, % 20.0 23.7 0.46
LVG n  145 n  139
EDVI (ml/m2) 66.2 16.2 71.0 20.6 0.13
ESVI (ml/m2) 32.6 12.1 35.1 15.4 0.39
EF (%) 51.3 11.9 51.3 11.9 0.99
LVG at 6-month follow-up n  103 n  113
EDVI (ml/m2) 68.2 18.2 71.8 23.5 0.31
ESVI (ml/m2) 29.9 13.9 31.7 16.3 0.47
EF (%) 57.1 12.5 56.7 12.3 0.77
BNP at 6-month follow-up n  93 n  80
BNP 77.4 91.0 101.6 128.0 0.07
BNP brain natriuretic peptide; EDVI end-diastolic volume index; EF ejection fraction; ESVI
 end-systolic volume index; LVG  left ventriculography; MLD  minimum lumen diameter;
QCA quantitative coronary angiography.
Table 5. Clinical Outcome In-Hospital and at 8-Month Follow-Up
Thrombus
Aspiration
No Thrombus
Aspiration
p
Value
In-hospital n  178 n  171
MACE 1 (0.6%) 2 (1.2%) NS
Death 1 1 NS
MI 0 1 (SAT) NS
TLR 0 1 NS
PCI 0 1 NS
CABG 0 0 NS
8-month follow-up n  170 n  158
MACE 22 (12.9%) 33 (20.9%) 0.05
Death 2 1 NS
MI 0 1 NS
TLR 20 31 0.05
PCI 18 30 0.05
CABG 2 1 NS
CABG coronary artery bypass grafts; MACEmajor adverse cardiac events; MImyocardial
infarction; SAT subacute thrombosis; TLR target lesion revascularization; other abbreviationsdas in Table 1.atients with myocardial infarctions of 12-h duration.
he primary end point of this study was the magnitude of
T-segment resolution at 1 h, which was improved in the
-Sizer group compared with the conventional therapy
roup (7.5 mm vs. 4.9 mm, p  0.033). Although the
ccurrence of distal embolization was reduced with the use
f X-Sizer (2% vs. 10%), equivalent rates were seen for
IMI flow grade 3, myocardial blush grade 3, and 6-month
ajor adverse cardiac and cerebral events. In the
-TRACT (Prospective Randomized Trial of Throm-
oatherectomy with the X-Sizer in Native Coronary Arter-
es and Saphenous Vein Grafts) study (30), a total of 797
onsecutive patients undergoing stent implantation in vein
rafts (72%) or native coronary artery containing thrombus
28%) were prospectively randomized to X-Sizer catheter or
o usual care followed by PCI groups. The rates of no
eflow, distal emboli, myocardial infarction, as well as
0-day rate of major adverse cardiac events were similar
etween the groups.
Despite of the marginal 36% difference in the incidence
f the primary end point between groups, the VAMPIRE
tudy showed several potential benefits of the upfront
spiration as reported in other studies (31–33). The TIMI
ow grades 2 or 3 were achieved in 90% of cases immedi-
tely after aspiration, which may facilitate selection of PCI
evice sizes as it provides early information about the size of
Table 6. Subgroup Analysis of Early and Late Reperfusion on Primary
End Points
Thrombus
Aspiration
No Thrombus
Aspiration
p
Value
Slow ﬂow/no reﬂow
Early reperfusion 12.2% (n 123) 15.3% (n 111) 0.38
Late reperfusion 8.1% (n 36) 37.6% (n 41) 0.01
Final myocardial blush
grade 3, %
Early reperfusion 43.9% (n 123) 18.9% (n 111) 0.001
Late reperfusion 51.4% (n 35) 21.9% (n 41) 0.03
Final TIMI ﬂow grade 3, %
Early reperfusion 87.8% (n 123) 84.7% (n 111) 0.38
Late reperfusion 91.9% (n 36) 63.4% (n 41) 0.01
Final cTFC
Early reperfusion 26.0 17.4 (n 121) 26.9 15.5 (n 111) 0.34
Late reperfusion 25.5 16.8 (n 35) 32.9 18.8 (n 40) 0.04
TLR (PCI or CABG)
Early reperfusion 11.8% (n 119) 17.2% (n 105) 0.25
Late reperfusion 9.1% (n 33) 29.7% (n 37) 0.03
MACE
Early reperfusion 13.5% (n 119) 18.1% (n 105) 0.34
Late reperfusion 12.1% (n 33) 32.4% (n 37) 0.04
Early reperfusion included patients who arrived at hospital within 6 h from the onset. Late
reperfusion included patients who arrived at hospital from 6 h to 24 h from the onset.
Abbreviations as in Tables 1, 2, 3, and 5istal artery as well as location and length of the target
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430esion. The higher incidence of TIMI flow after aspiration
ay also help explain the lower coronary dissection observed
n the treatment arm. The procedure time or time to
eperfusion was not affected by the use of 1 additional device
n the TVAC group. The time to perform thrombectomy
nd primary PCI in the present study is relatively shorter
han in previous reports, which may explain the difference in
utcomes between studies (11–13,29). Furthermore, there
as a high rate of macroscopic thrombus or plaque debris
spirated in our study. The flexibility, low crossing profile,
nd the activation of suction during insertion of the TVAC
atheter prior to crossing the obstruction, may have resulted
n lower distal embolism in this study.
Although a major adverse clinical event was not a primary
nd point of this study, the 38% reduction in the incidence
f clinical events, primarily due to lower target lesion
evascularization rates, observed in the aspiration group is
oticeable. Whether removal of inflammatory debris and
ctive thrombus material from the target lesion prior to
tenting explain the low clinical restenosis rates observed in
he present study remains to be confirmed by studies
roperly designed to test such a hypothesis. Finally, our
tudy provides strong pilot evidence that patients presenting
ate after symptoms onset benefit the most from upfront
hrombectomy during primary PCI. Conventional primary
CI in this subgroup is associated with worse outcomes
han in those presenting earlier after symptoms (34). Con-
ersely, angiographic and clinical outcomes were essentially
qualized between early and late reperfusion patients when
oth populations were treated with a strategy of upfront
hrombectomy prior to primary PCI.
tudy limitations. Not using glycoprotein IIb/IIIa inhibitors
ay be a limitation of this study because their use could
nfluence outcomes whose pathogenesis involves platelet
hrombi. However, the use of glycoprotein IIb/IIIa inhibi-
ors has not uniformly produced enhanced clinical outcomes
n clinical trials (35). Future studies could investigate the
nteraction between glycoprotein IIb/IIIa inhibitors and
hrombectomy devices in the setting of STEMI.
onclusions
he VAMPIRE study showed the marginal benefit of
hrombectomy on myocardial perfusion. In a post hoc
nalysis, patients with late reperfusion of between 6 and
4 h benefited most from the thrombectomy. The effective-
ess of thrombectomy for STEMI may deserve re-
valuation with a simple upfront thrombus aspiration strat-
gy using an efficient device in a refined study design.
The study was not designed, and consequently is under-
owered, to detect major differences in isolated clinical end
oints such as myocardial infarction and death. Our data
ay not apply to the overall population presenting withTEMI as differences in specific technical aspects of therocedure, such as time to balloon inflation, aspiration
evices, and mode of aspiration may differ between institu-
ions and countries. Nevertheless, our results support the
oncept that upfront thrombectomy in patients with acute
TEMI undergoing primary PCI is safe and may improve
cute reperfusion and clinical outcomes, particularly in
atients presenting later after symptoms onset. Taken to-
ether, the knowledge accumulated with other studies
nvestigating similar hypotheses and the present data war-
ant further attempts to develop rheolytic strategies to
mprove outcomes of the high-risk population presenting
ith STEMI.
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his article.
